ABSTRACT: The functional polymorphism that explains the established association of Fc gamma receptor IIIb (FCGR3B) with Graves' disease (GD) and Graves' ophthalmopathy (GO) remains unidentified, but copy number variation (CNV) might be relevant. The aim of this study was to determine whether CNV for FCGR3B is associated with GD and GO. Genotype analysis involved 624 GD patients, including 397 without GO (GDnonGO) and 227 with GO (GDGO), and 227 healthy controls. The relative copy number (CN) of FCGR3B was determined using a relative real-time quantitative polymerase chain reaction. Our findings indicated the distribution of the relative CN of FCGR3B significantly differed between the GDGO patients and the healthy controls (p = 0.02) but not between the total GD patients and the healthy control groups (p = 0.06). Individuals with less than 2 CN or more than 2 CN of FCGR3B were at significantly decreased risk of developing GDGO. In addition, GD patients with less than 2 copies of FCGR3B were at reduced risk for developing nodular hyperplasia and vitiligo, but at increased risk for myxedema. Our results suggest that CNV of FCGR3B is associated with the development or progression of GD in Taiwan Chinese population.
INTRODUCTION
Graves' disease (GD) is an autoimmune disease characterized by hyperthyroidism, diffuse goitre, thyroidspecific autoantibodies with or without Graves' ophthalmopathy (GO), and dermopathy due to the circulating autoantibodies 1 . GO is the most common extrathyroid manifestation of GD and affects 25%-50% of GD patients [2] [3] [4] [5] . Approximately 28% of patients with GO present with severe disease, with restricted mobility, diplopia, keratopathy, and optic neuropathy 6, 7 . Numerous functionally relevant singlenucleotide polymorphism (SNP) variants have been characterized in GD and GO, although none have yet proven causative 8 . Other forms of variation that might affect gene expression should also be considered.
Copy number variation (CNV) is recognized as a common form of genomic variation in which DNA segments (> 1 kb) are present in a variable number of copies compared to a reference genome. A CNV caused by genomic rearrangements such as deletions, duplications, inversions, and translocations may contribute to alteration of gene expression and subsequent phenotypic variation, which results in susceptibility or resistance to disease [9] [10] [11] . CNV has also been associated with autism [12] [13] [14] [15] , schizophrenia [16] [17] [18] [19] , cancer [20] [21] [22] [23] [24] [25] , and autoimmune disease 11, [26] [27] [28] [29] [30] . Fc gamma receptor IIIb (FCGR3B), the CD16 cell surface immunoglobulin receptor, located on chromosome 1q23, is a low-affinity IgG receptor that binds with IgG complexes at the Fc region 31 . FCGR3B belongs to the Fc gamma receptor famwww.scienceasia.org ily, which contributes to the regulation of acquired and innate immunity 31 . Studies have shown that a lower copy number of FCGR3B can increase the susceptibility to systemic autoimmune diseases such as systemic lupus erythematosus and other autoimmune disorders 27 . Although there have been major advances in understanding the genetic basis of GD 27 , the association between the variation of copy number in FCGR3B gene and the risk of GO remains unclear. In the present study, the variant in the FCGR3B gene that may explain the association between, and the physiological impact of, CNV in this region and the development of GD and GO was found.
MATERIALS AND METHODS

Subjects
A disease group with 624 patients with a confirmed diagnosis of GD and an appropriate control group with 227 healthy volunteers with matched gender according to the female predominance of GD including 32 male (20.0%) and 128 female (80.0%) at China Medical University Hospital in Taiwan were enrolled and actively followed. The methods of diagnosis of GD and classification of GO were as previously described 32 . All individuals classified as affected were interviewed and examined by experienced clinicians. Demographic and clinical characteristics of 624 patients with GD are summarized in Table 1 . The study was approved by the institutional review board and the ethics committee of China Medical University Hospital (DMR96-IRB-109; approved 2007 September). Written informed consent was obtained from each participants in accordance with institutional requirements and the Declaration of Helsinki Principles.
Genomic DNA extraction
The genomic DNA was extracted from peripheral blood leukocytes of participants using the Genomic DNA kit (Qiagen) according to the manufacturer's instructions. Considering that the quantitative polymerase chain reaction (qPCR) technique is sensitive to small variations in DNA quality 33 , the quality of each genomic DNA was verified on an agarose gel and the template DNA were freshly diluted from 200 µg/ml stock and used within 2 weeks.
Analysis of FCGR3B copy number variants
The relative CN of the FCGR3B gene in each individual was estimated using a relative real-time qPCR method that is suited to larger-scale genotyping. This method has been tested and proven to provide reliable results. Specific TaqMan probes (Assay ID: Hs04211858 cn) for FCGR3B and for a reference gene RNase P (RNaseP part number 4403326) were purchased from ABI Biosciences (Applied Biosystems, Foster City, CA, USA). The TaqMan probes for FCGR3B and RNase P were labelled with FAM and VIC, respectively. Polymerase chain reactions were run on an ABI 9700 machine. Amplification reactions (15 µl) were carried out using genomic DNA (10 ng), TaqMan Copy Number Reference Assay for FCGR3B and RNase P, and TaqMan Master Mix. Thermal cycling was initiated with an initial denaturation step of 10 min at 95°C, followed by 40 cycles each of 15 s at 95°C and of 1 min at 60°C. A dissociation procedure was performed to generate a melting curve to confirm amplification specificity. The relative FCGR3B CN for each individual was estimated using the 2 −∆∆Ct method, where Ct is cycle threshold, −∆Ct = (Ct gene − Ct reference ) as described previously 34 . The PCR products were quantified in triplicate, and the standard deviation and coefficient of variation (CV) were calculated based on 3 runs. To control for reaction quality, each reaction plate also included a calibrator, a positive control, and a no-template control (NTC). Data from a plate were included if the calibrator CV was less than 5%, the positive control CV and sample CVs were all less than 10%, and the NTC was negative. To include acrossplate data, the CVs of the positive control had to be similar and the NTC had to be negative.
Statistical analysis
Significance of the differences between the distributions of FCGR3B CN in cases and controls was estimated by Chi square test or Fisher's exact test. Odds ratios (OR) and confidence intervals (CI) were estimated by logistic regression models using SPSS 12.0. The CN equal to two (CN = 2) was chosen as reference category for FCGR3B. To estimate OR, bins of CN were grouped as 0-1 CNs for FCGR3B (< 2 category), 3-5 CN for FCGR3B (> 2 category). We estimated the risk of acquiring disease associated with CNs for FCGR3B categories by comparing them with a reference CN category. For each of these categories, an OR > 1 indicates a detrimental effect of CNV on disease susceptibility, and OR < 1 indicates a protective effect of CNV.
RESULTS
Correlation between CNV of FCGR3B and the development of GD and GO
The distribution of FCGR3B copy number (CN) according to the presence of GD or GO is summarized in Table 2 . The distribution of FCGR3B CN was not statistically significant different between health controls and GD (p = 0.06). Further, we separated GD patients into 2 groups according to GO status. The distribution of FCGR3B CN was significantly different between healthy control and GD GO patients (p = 0.0176) but not with GD nonGO patients (p = 0.14). Our results revealed that individuals with FCGR3B copy number not equal to 2 were at significantly decreased risk of developing GD GO when compared to individuals with 2 copies of FCGR3B (odds ratio (OR) = 0.45, 95% confidence interval (C.I.): 0.24, 0.84 and OR = 0.66, 95% C.I.: 0.42, 1.06 for CN < 2 and CN > 2, respectively) ( Table 2 ). The result (control versus GD GO patients) was statistical significant after Bonfferoni correction (p = 0.035). Regression analysis with or without gender and age as covariates did not affect the significance of the reported association results. The results suggest that FCGR3B CNV might not be associated with the development or progression of GD, but could be associated with the development or progression of GD GO .
Correlations between CNVs of FCGR3B and clinical phenotypes
The association between clinical features of GD patients and CNV of FCGR3B was analysed. The results are summarized in Table 3 . No significant difference for FCGR3B CNV was found between GD patients and different stages of goitre (p = 0.47). Interestingly, the distribution of FCGR3B CNV significantly differed between GD patients with different patterns of nodular hyperplasia (p = 0.02), myxoedema (p = 0.04), and vitiligo (p = 0.02). As shown in Table 3 , individuals with less than 2 copies of FCGR3B were Abbreviations: CN, copy number. GDtotal, total Graves' disease patients. GDnonGO, Graves' disease patients without ophthalmopathy. GDGO, Graves' disease patients with ophthalmopathy. N (%), number (percentage). OR (95% C.I.), odds ratio (95% confidence interval). a Odds ratio and 95% C.I. were estimated by applying unconditional logistic regression when compared GDGO with normal control. b P value was calculated by chi square test (2 × 3 tables) and was considered significant when less than 0.05. 
DISCUSSION
Several functionally relevant SNP variants are characteristic of GD and GD GO 8 , but few studies have demonstrated an association between CNV and GD 27, 35, 36 . Here, we found that CNV in FCGR3B significantly differs between GD GO patients and healthy controls. Individuals with more or fewer than 2 copies of FCGR3B may have reduced susceptibility to GD GO . In addition, our data showed the protective effect of FCGR3B CNV on GD which was consistent with previous studies in a Caucasian population 27 , although the results in both studies did not reach the statistical significance. The sample size of this study did not reach 80% power for the given effect size and is a limitation. In addition, the genetic backgrounds of ethnically diverse populations should be considered. Niederer et al 37 identified significant differences in FCGR3B CNV distribution among Caucasian, East Asian, and Kenyan population. Therefore, confirmation of these results by studies with larger sample sizes and in different population is warranted. More- over, GD patients with 2 copies of FCGR3B are at significantly increased risk for the development of nodular hyperplasia and vitiligo, but at reduced risk for myxoedema.
FCGR3B, which is expressed by neutrophils and eosinophils, functionally links the humoural and cellular branches of the immune system and plays an important role in the activation and modulation of the immune response 31 . FCGR3B CNV correlates with protein expression, soluble serum FcγRIIIb, neutrophil uptake of and adherence to immune complexes, and macrophage overactivity 38 . Dysregulation of FcγRIIIb expression may contribute to the impaired clearance of immune complexes. In GD/GD GO , in which immune complexes may not play an important role, the relation between FCGR3B CNV, FCGR3B expression, and neutrophil activation may require further investigation.
In addition, FCGR3B CNV could play a different role involving other co-regulatory genes, in the development of systemic and organ-specific autoimmunity. An association between low FCGR3B CNV and systemic lupus erythematosus has been reported in Caucasians 27 . However, anti-neutrophil cytoplasmic antibody-associated systemic vasculitis, an autoimmune disease in which immune complex deposition plays only a minor role, seems to be diversely associated with FCGR3B CN 27 . Also, linkage disequilibrium between multi-allelic FCGR3B CNV and SLEassociated SNPs in the FCGR locus was defined 37 . However, the associations between NA1/NA2 allelic variant of FCGR3B with GO or GD in our study were not significant (p value > 0.05). Further study of the genetic interaction between FCGR3B and other genes, such as FCGR2A, FCGR2B, and complement receptor 3 (CR3) should be considered.
In summary, this study suggests that FCGR3B CNV is associated with the development or progression of GD and GO, thereby providing new information on the implications of FCGR3B CNV in patients with GD.
